Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines
Not Applicable
Completed
- Conditions
- Facial RhytidesGlabellar Frown Lines
- Interventions
- Biological: botulinum toxin Type ADrug: Normal Saline
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 175
- Registration Number
- NCT01391299
Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis
Phase 3
Completed
- Conditions
- Eyelash Hypotrichosis
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Allergan
- Target Recruit Count
- 173
- Registration Number
- NCT01391273
Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis
Phase 3
Completed
- Conditions
- Eyelash Hypotrichosis
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Allergan
- Target Recruit Count
- 36
- Registration Number
- NCT01391286
Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
Completed
- Conditions
- Muscle Spasticity
- Interventions
- Biological: botulinum toxin Type A
- First Posted Date
- 2011-07-04
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 108
- Registration Number
- NCT01387074
Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia
Phase 4
Completed
- Conditions
- Torticollis
- Interventions
- Biological: botulinum toxin Type A
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2011-06-29
- Lead Sponsor
- Allergan
- Target Recruit Count
- 28
- Registration Number
- NCT01384214
Retrospective Study of Patients With Spasticity in the Spanish Population
Completed
- Conditions
- Muscle Spasticity
- Interventions
- Other: No treatment
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 235
- Registration Number
- NCT01383681
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
Phase 2
Completed
- Conditions
- AlopeciaBaldnessAlopecia, Androgenetic
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 307
- Registration Number
- NCT01325337
Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
Phase 2
Completed
- Conditions
- BaldnessAlopecia
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 306
- Registration Number
- NCT01325350
Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye
Phase 1
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%Drug: cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%Drug: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation BDrug: cyclosporine ophthalmic emulsion Formulation ADrug: cyclosporine ophthalmic emulsion Formulation B
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Allergan
- Target Recruit Count
- 44
- Registration Number
- NCT01319773
Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Completed
- Conditions
- Vitrectomy
- Interventions
- Procedure: Pars Plana Vitrectomy
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Allergan
- Target Recruit Count
- 25
- Registration Number
- NCT01319318
© Copyright 2025. All Rights Reserved by MedPath